Orthocell Limited (ASX: OCC) has received regulatory approval from Singapore’s Health Sciences Authority (HSA) for Striate+, its market-leading dental membrane used in guided bone regeneration. This milestone opens the door for immediate sales in Singapore and strengthens Orthocell’s expanding global footprint.
Why This Approval Matters
Singapore is a key regional hub for advanced medical treatments and serves as a gateway to other ASEAN markets. With existing approvals in the US, Europe/UK, Australia, New Zealand, and Canada, this latest clearance further validates Orthocell’s high-quality products and manufacturing standards.
Orthocell’s global marketing and distribution partner, BioHorizons, is already well-established in Singapore, meaning a fast transition to first sales and revenue generation is expected.
Striate+ Gaining Momentum in a $1 Billion Market
Striate+ is experiencing strong global sales growth, thanks to overwhelmingly positive feedback from dental surgeons. Its 98.6% success rate in post-market clinical studies has helped drive adoption in a global market opportunity valued at over AU$1 billion.
Beyond Singapore, Orthocell is fast-tracking approvals in new markets, including Brazil, where clearance is expected within the next 3–6 months.
Financial Strength & Expansion Plans
With a strong balance sheet of approximately AU$33 million in cash, Orthocell is well-funded to continue expanding its global commercial footprint. The company aims to capture a 20% share of the addressable market, with additional growth expected as new regulatory approvals come through.
Orthocell CEO Paul Anderson welcomed the news, stating:
“This approval reinforces our reputation for high-quality medical products and enhances our ability to drive revenue growth as BioHorizons expands into global markets.”
With Singapore secured and further expansion on the horizon, Orthocell is well-positioned for continued growth and increasing shareholder value.
